Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

armasset.com">kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Clevudine will not demonstrate any additive antiviral benefit in combination with tenofovir in the head-to-head study, the risk that Clevudine will not demonstrate superiority over Hepsera in Clevudine's ongoing Phase 3 registration study, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Viread and Hepsera are registered trademarks of Gilead Sciences, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... CAMBRIDGE, Mass. , April 20, 2015 /PRNewswire/ ... updated and final clinical results for the Phase ... doxorubicin, in HER2-positive metastatic breast cancer.  The results ... a clinical trials plenary oral session at the ... Meeting in Philadelphia, PA. ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes the ... US$ Million by the following Product Segments: Sphygmomanometers (Aneroid Sphygmomanometers, ... Pressure Transducers. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts are provided ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5World Blood Pressure Monitoring and Measurement Instruments Industry 2World Blood Pressure Monitoring and Measurement Instruments Industry 3World Blood Pressure Monitoring and Measurement Instruments Industry 4World Blood Pressure Monitoring and Measurement Instruments Industry 5World Blood Pressure Monitoring and Measurement Instruments Industry 6World Blood Pressure Monitoring and Measurement Instruments Industry 7World Blood Pressure Monitoring and Measurement Instruments Industry 8World Blood Pressure Monitoring and Measurement Instruments Industry 9World Blood Pressure Monitoring and Measurement Instruments Industry 10World Blood Pressure Monitoring and Measurement Instruments Industry 11World Blood Pressure Monitoring and Measurement Instruments Industry 12World Blood Pressure Monitoring and Measurement Instruments Industry 13World Blood Pressure Monitoring and Measurement Instruments Industry 14World Blood Pressure Monitoring and Measurement Instruments Industry 15World Blood Pressure Monitoring and Measurement Instruments Industry 16World Blood Pressure Monitoring and Measurement Instruments Industry 17World Blood Pressure Monitoring and Measurement Instruments Industry 18World Blood Pressure Monitoring and Measurement Instruments Industry 19World Blood Pressure Monitoring and Measurement Instruments Industry 20World Blood Pressure Monitoring and Measurement Instruments Industry 21World Blood Pressure Monitoring and Measurement Instruments Industry 22World Blood Pressure Monitoring and Measurement Instruments Industry 23World Blood Pressure Monitoring and Measurement Instruments Industry 24World Blood Pressure Monitoring and Measurement Instruments Industry 25World Blood Pressure Monitoring and Measurement Instruments Industry 26World Blood Pressure Monitoring and Measurement Instruments Industry 27World Blood Pressure Monitoring and Measurement Instruments Industry 28
... SAN MATEO, Calif., July 1, 2011 Sonitus Medical, Inc., ... and removable hearing device to transmit sound via the teeth, ... for its SoundBite Hearing System. The FDA 510(k) clearance for ... device and marks another significant milestone for the company. ...
... Alere Inc. (NYSE: ALR ) ("Alere") ... facilities totaling $2.1 billion.  Jefferies Finance LLC, GE Capital ... acted as joint lead arrangers for the credit facilities, ... agent for the lenders under the credit facilities. ...
Cached Medicine Technology:Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System 2Alere Inc. Announces $2.1 Billion Credit Facilities 2
(Date:4/20/2015)... Global Lyme Alliance (GLA) announced today that its ... Hyatt Regency Greenwich, raised over $850,000 to fund research ... tick-borne diseases. , “We are extremely grateful to ... this year’s Gala such a success,” said Robert Kobre, ... initiatives to ultimately find a cure for Lyme ...
(Date:4/20/2015)... 20, 2015 Mauritius is a seemingly ... Located some 2,000 km (1,243 miles) off the southeastern ... cultural and religious melting pot where everyone lives together ... darker reality. Mauritius is riddled with drug abuse. In ... of opiate consumption of any nation in eastern Africa. ...
(Date:4/20/2015)... IL (PRWEB) April 20, 2015 ... Inc., has secured nationally-renowned Gastroenterologist Lawrence Kosinski, MD, ... , Dr. Kosinski brings a unique combination ... vision to the Mutare Health team ... improved communication, collaboration, and quality of care in ...
(Date:4/20/2015)... Novatus, a leading provider of ... service level to the growing European market by ... Paris. After a rigorous review process Novatus ... resilience, security and operational expertise, and extensive connectivity. ... as we expand our footprint and capabilities to ...
(Date:4/20/2015)... New York, New York (PRWEB) April 20, 2015 ... the trade association representing the U.S. health insurance ... as a result of the recent controversy involving ... In a letter to U.S. Senator Robert Casey ... the safety concerns surrounding uterine morcellation point to ...
Breaking Medicine News(10 mins):Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 3Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Novatus Expands into European Data Centers 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4
... delivering,albuterol, a fast-acting bronchial dilator, currently use propellants such ... December 31st,2009, or replacement HFA,s. Both propellants are also ... near-supersonic speeds. , ... of air by ejecting,the medication from a microfluidic pump ...
... without health insurance for all or some of 2007, according ... for Health Policy Research. , Drawing ... (CHIS), the policy brief,s authors found that 6.4 million Californians ... 2007, the most recent year for which comprehensive statewide data ...
... profiling, In-Stream profiling, data quality and MDM discovery solutions announces today ... (MMA), joining Microsoft Corp. and other key industry partners working together ... the Microsoft® platform. , ... Chicago, IL (PRWEB) December ...
... brand jeans appeal to people who seek intimacy in ... According to a new study in the Journal ... their brand choices. , In psychology, different relationship ... Vanitha Swaminathan, Karen M. Stilley (University of Pittsburgh), and ...
... particular gene could put brakes on killer disease, scientists ... produced by a particular gene may provide a new ... , Experiments at the Mayo Clinic College of Medicine ... down a key pathway in another gene that, in ...
... Mediocre or Near-Failing Grades , , ... care system mean more people than ever before are relying on ... mediocre C- grade for it support of emergency patients, according to ... Dr. Nicholas Jouriles, president of the American College of Emergency Physicians ...
Cached Medicine News:Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:Nearly 6.4 million Californians lack health insurance, report shows 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3Health News:Filling in the gaps: Personality types lead people to choose certain brands 2Health News:Pancreatic Cancer May Have a New Foe 2Health News:VIDEO from Medialink and ACEP: Nation's Failure to Support Emergency Patients Graded C- in National Report Card 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: